Cellink designs and develops bioprinting technologies that enable researchers to 3D print organs and tissue for applications that span industries, from pharmaceutical to cosmetic.
They are the first bioink company in the world – their innovative and patent-pending bioink is a biomaterial innovation enabling human cells to grow and thrive just as they would in the natural human body environment.
“Bioinks are the engines of the bioprinting field,” says Patrick Thayer, PdD, who is also the Bioink Officer at Cellink. “They are what the cells grow in. They are what the cells remodel. They are what will constitute the engineered tissues of tomorrow.”
The Gothenburg-based company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products and, in the future, clinical applications.
Today, Cellink’s disruptive technology platform is being used to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors which can then be used to develop new cancer treatments.
They have also created the first 3D bioprinted cornea, and recently produced the first holographic bioprinter – Holograph X.
Within 12 months, Cellink have commercialized products in more than 50 countries. They have sold to hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and the FDA.